Table 2 |
|||||||
|
Relationship analysis between positive rate of XIAP/Smac and clinicopathologic variables |
|||||||
|
n* |
XIAP-C |
Smac |
XIAP-N |
||||
|
|
|
|
|||||
|
PR |
P value |
PR |
P value |
PR |
P value |
||
|
|
|||||||
|
Age |
|||||||
|
<50 |
49 |
42(85.7%) |
20(40.8%) |
21(42.9%) |
|||
|
≥50 |
53 |
0.789 |
0.145 |
1.000 |
|||
|
Size |
44(83.0%) |
14(26.4%) |
23(43.4%) |
||||
|
≤5 cm |
77 |
67(87.0%) |
26(33.8%) |
33(42.9%) |
|||
|
>5 cm |
25 |
19(76.0%) |
0.212 |
8(32.0%) |
1.000 |
11(44.0%) |
1.000 |
|
LN status |
|||||||
|
N0 |
39 |
33(84.6%) |
14(35.9%) |
14(35.9%) |
|||
|
N1-3 |
63 |
53(84.1%) |
1.000 |
20(31.7%) |
0.672 |
30(47.6%) |
0.305 |
|
Grade |
|||||||
|
I |
25 |
22(88.0%) |
10(40.0%) |
13(52.0%) |
|||
|
II-III |
77 |
64(83.1%) |
0.755 |
24(31.2%) |
0.468 |
31(40.3%) |
0.356 |
|
ER |
|||||||
|
positive |
39 |
31(79.5%) |
14(35.9%) |
20(51.3%) |
|||
|
negative |
63 |
55(87.3%) |
0.401 |
20(31.7%) |
0.672 |
24(38.1%) |
0.221 |
|
PR |
|||||||
|
positive |
44 |
36(81.8%) |
18(40.9%) |
23(52.3%) |
|||
|
negative |
58 |
50(86.2%) |
0.591 |
16(27.6%) |
0.204 |
21(36.2%) |
0.112 |
|
HER2 |
|||||||
|
positive |
94 |
78(83.0%) |
34(36.2%) |
41(43.6%) |
|||
|
negative |
8 |
8(100.0%) |
0.351 |
0(0.0%) |
0.049 |
3(37.5%) |
1.000 |
|
XIAP-N |
|||||||
|
positive |
44 |
41(93.2%) |
16(36.4%) |
/ |
|||
|
negative |
58 |
44(75.9%) |
0.030 |
18(31.0%) |
0.672 |
/ |
|
|
|
|||||||
|
n*: number of cases. PR: positive rate. LN: lymph node. XIAP-C and XIAP-N denoted cytoplasmic immune staining score and nuclear labeling of XIAP, respectively. P-values (two sided) < 0.05 were highlighted in bold. |
|||||||
|
Zhang et al. Diagnostic Pathology 2011 6:49 doi:10.1186/1746-1596-6-49 |
|||||||
